|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
This great trading action comes in an environment with so many dramatic news headlines.
Stick to themes like biotechnology, SPACs, EV batteries, and others.
Biotechnology is always high risk but the right plays move unlike anything else.
Anyone attempting to navigate this market based on macro-economic analysis is going to have a tough time.
A close below $44 will cause the bulls to throw in the towel and gains above $68 will do the same to the bears.
As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.
As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.
There's no advantage in trying to predict the next move right now.